. **Markers for Mortality in COVID 19 patients with Atrial Fibrillation or Flutter** Chan, KH, MD; Patel, B, MD; Farouji, I, MD; Suleiman, A, MD; Slim, J, MD Saint Michael's Medical Center, New York Medical College, Newark, New Jersey

BACKGROUND:

Severe Acute Respiratory Syndrome Co 2 (SARS-CoV-2) infection can lead to different cardiovascular complications.

AIM:

we were interested in studying prognostic markers in patients with atrial fibrillation/flutter.

STUDY:

✓ Retrospective cohort study

INCLUSION CRITERIA:

- $\checkmark \geq 18$ years with confirmed COVID-19 and either with existing or new onset atrial fibrillation/flutter
- \checkmark Admitted to our hospital between March 15, 2020 and May 20, 2020.

EXCLUSION CRITERIA:

✓ Does not fulfil above criteria ✓ Still in hospital on May 20, 2020

ANALYSIS:

- Demographic, clinical outcome and laboratory data were extracted from the electronic medical record and compared between survivors and nonsurvivors.
- Univariable analysis and multivariable logistic regression methods were employed to identify the prognostic markers associated with mortality in patients with atrial fibrillation/flutter.

oronavirus	
many	

	All Patients	Survival	Expired	p-value		All Patients	Survival	Expired	p-valu
Clinical Charac	(n=37)	(n=16)	(n=21)			(n=37)	(n=16)	(n=21)	
Age (Mean ±	72.22 ± 15.75	$71.69 \pm$	72.62 ±	0.8615	Laboratory Prof				
SD)	12.22 - 13.13	15.09	16.60	0.0015	Complete Blood				0 0 5 0
Gender		13.09	10.00		ANC	7.23 ± 0.72	6.45 ± 1.11	7.82 ± 0.94	0.350
Male	19 (51%)	8 (50%)	11 (52%)	0.8897	ALC	1.08 ± 0.12	1.32 ± 0.17	0.90 ± 0.17	0.096
Female	19 (3170) 18 (49%)	8 (50%)	10(48%)	0.009/	AMC	0.62 ± 0.06	0.76 ± 0.11	0.51 ± 0.05	0.035
Ethnicity	10 (49/0)	8 (3070)	10 (40/0)		Platelets	243 ± 15.88	286.5 ± 22.19	209.9 ± 19.78	0.014
Latino	7 (19%)	$\int (\int 0/)$	7 (33%)		Inflammatory M	larkers			
		0(0%)		0.0370	Ferritin	1038 ± 173.8	627.9 ± 161.8	1351 ± 263.7	0.037
Black Caucasian	21(57%)	11 (69%)	10(48%)		D-dimer	6825 ± 3495	2333 ± 941.4	10248 ± 6072	0.267
	9 (24%)	5 (31%)	4 (19%)		CRP	11.95 ± 1.53	9.294 ± 1.84	13.97 ± 2.23	0.130
Comorbidities	27(720/)	1/(000/)	12(620/)	0.0067	LDH	388.4 ± 25.54	321.8 ± 35.92	439 ± 32.15	0.020
HTN	27(73%)	14(88%)	13(62%)	0.0867	Cardiac Profile				
DM CAD/CHF	15(41%) 10(27%)	6(38%) 5(210/)	9(43%) 5(240/)	0.7507	Troponin	0.1544 ± 0.05	0.048 ± 0.12	0.23 ± 0.09	0.099
	10 (27%)	5 (31%)	5 (24%)	0.6253	BNP	508.8 ± 162.2	434.5 ± 133.6	560.8 ± 262.2	0.6707
Need of	O(220/)	(120/)	(200/)	0 2204	Miscellaneous				
Mechanical Ventilation	8 (22%)	2 (13%)	6 (29%)	0.2394	NLR	13.67 ± 2.45	5.76 ± 1.09	19.32 ± 3.69	0.004′
Atrial fibrillatio	n/Atrial fluttor				NMR	15.07 ± 2.10 15.27 ± 2.21	9.90 ± 1.59	19.32 ± 3.09 19.36 ± 3.47	0.031
New onset	23 (62%)	10 (63%)	13 (62%)	0.9705	LMR	2.04 ± 0.25	2.10 ± 0.33	1.99 ± 0.37	0.829
			8 (38%)	0.9703	PLR	336.70 ± 46.10	$252.80 \pm$	400.6 ± 77.10	
Existing	14 (38%)	6 (37%)	0 (3070)			JJ0.70 ± 40.10	232.80 -	-00.0 <u>-</u> //.10	0.113/
Table 1: Demogra fibrillation/atrial f (HTN – Hypertensic CHF – Congestive h	on, DM – Diabetes m	•			Table 2: Non-para(ANC - Absolute neumonocyte count, CRInatriuretic peptide, Nratio, LMR – Lymphe	trophil count, ALC - P – C-reactive protei LR – Neutrophil-lyr	- Absolute lympho n, LDH – Lactate nphocyte ratio, NI	cyte count, AMC dehydrogenase, B LR – Neutrophil-n	- Absolut NP – Bra nonocyte

Discussion and Conclusion:

✓ With multivariable logistic regression analysis, the only value that had an odds of survival was a low NLR (odds ratio [OR], 0.74; 95% confidence interval [CI], 0.53-0.93).

✓ This retrospective cohort study of hospitalized patients with COVID-19 demonstrated an association of increase NLR as risk factors for death in COVID-19 patients with atrial fibrillation/flutter.

✓ A high NLR has been associated with increased incidence, severity and risk for stroke in atrial fibrillation patients

✓ To our knowledge, we are first to demonstrate the utilization in mortality predictions in COVID-19 patients with atrial fibrillation.



